Dr Perez talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about a debate she took part in on the use of Avastin (Bevacizumab) for metastatic breast cancer and also her recent analysis of HER2 breast cancer tests, revealing issues with reliability. Results for testing breast tumours for HER2 proteins and genes are most often straightforward when one piece of tumour is analyzed. However tumours can be diverse and Dr Perez’s research found that HER2 results can vary in up to 10 percent of patients when several tumour blocks are analysed. This could have impact in the clinic.